Monoclonal antibody | |
---|---|
Type | ? |
Source | Human |
Target | colony stimulating factor 2 |
Clinical data | |
Synonyms | MORAb-022 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6726H10428N1764O2184S38 |
Molar mass | 152.1 g/mol |
Gimsilumab (MORAb-022) (INN [1] ) is a human monoclonal antibody designed for the treatment of rheumatoid arthritis.
Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects joints. It typically results in warm, swollen, and painful joints. Pain and stiffness often worsen following rest. Most commonly, the wrist and hands are involved, with the same joints typically involved on both sides of the body. The disease may also affect other parts of the body. This may result in a low red blood cell count, inflammation around the lungs, and inflammation around the heart. Fever and low energy may also be present. Often, symptoms come on gradually over weeks to months.
This drug was developed by Eisai Inc. [2]
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |